TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07846215: A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome

Sponsor: Newleos Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07846215 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07846215 Rescue Dossier →